Navigation Links
Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
Date:3/3/2008

nce to the cash flow statement, represents the net cash the Company spent in conducting its operational activities, excluding net proceeds resulting from its investment and financing activities. The Company's net burn rate in 2007 amounted to euro 29.5 million, compared to euro 17.8 million in 2006. This significant increase in the net burn rate, notwithstanding the increase in payments relating to collaboration and development agreements received by the Company, for an aggregate amount of euro 14.0 million in 2007, is explained by the significant increase in the operational expenses incurred by the Company in 2007. NicOx expects its burn rate to continue to further increase very strongly over the coming financial years, as a result of the anticipated expenses related to the clinical development and the launch preparation activities for its drug candidate naproxcinod, currently in phase 3 clinical development.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide-donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulm
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
3. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
4. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
7. Biopure Announces 2007 Third Quarter Financial Results
8. Xytis Names Gordon H. Busenbark as Chief Financial Officer
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Pharmacopeia Announces Third Quarter 2007 Financial Results
11. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC Bulletin Board: NWBO) announced today that the US Patent and Trademark Office has allowed its patent application o
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 1China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 2China Biotics Inc Announces Closing of Public Offering of Common Stock 58860 3VIDEO from Medialink and CIGNA 3A Dont Stress Out Over Stress Some of it is Good for You 58857 1VIDEO from Medialink and CIGNA 3A Dont Stress Out Over Stress Some of it is Good for You 58857 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 1Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 14351 4
...ngs Published in Blood Highlight Millennium Leader... the Role of VELCADE as,Foundation of Therapy in B...GE, Mass., April 17, 2007 /PRNewswire-FirstCall/ -...ood show that a,team of researchers led by Millenn...s which may lead to identifying multiple,myeloma p...
...nation Therapy Significantly Decreased Tumor Blood...umors -, LOS ANGELES and TUSTIN, Calif., April 17,...uticals, Inc. , a,clinical stage biopharmaceutical... for the treatment of cancer and hepatitis C,virus... data,presented at the Centennial Annual Meeting o...
Other Medicine Technology:Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 2Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 3Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 4Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 5Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection 6Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
(Date:12/4/2009)More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participa
Breaking Medicine News(10 mins):Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2
...tudy of its kind, a Mexican health care program cr... crippling health care costs among poorer househol...Popular program, and arise from an evaluation cond... establish that the program achieved its main goal...
...th in Long-Term Survivors of Hereditary Retinoblas...stoma are at an increased risk of death due to a s... Retinoblastoma is a very rare cancer of the eye ...he risk of death due to these subsequent cancers i...
...te have found that the growth factor known as TGF-... in the retina and that blocking it can cause reti...April 2 issue of PLoS ONE , may have an important...hey add to our understanding of the molecules that...
...ement of these growths needs to be tailored , ...e cancer cell can lead to multiple, anatomically d...e types of tumors usually look similar, but, until...dy by a team at the Indiana University School of M...
...e interventions in future, study finds , ,...ve treatment in the first two years after a diagno...ove patient survival, a new study finds. , Researc...ceived the most intensive treatment was $7,131 com...
...nd should be urged, expert says, , , TUESD...of moderate exercise will not harm people with hea... a new study has found. , That admittedly tepid co...e. , Some were started on a 36-session training pr...
Other Medicine News:Health News:Mexican health care program successful at reducing crippling health care costs 2Health News:Mexican health care program successful at reducing crippling health care costs 3Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Growth factor TGF-B helps maintain health of retinal blood vessels 2Health News:Single Cell May Produce Multiple Lung Cancer Tumors 2Health News:Intensive Early Treatment Doesn't Help Bladder Cancer Survival 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
...boratories is a national reference laboratory and ...ch and development. ARUP offers an extensive test ... clinical and anatomic pathology. Owned by the Uni...e more than half of the nation's university teachi...
Medicine Products: